Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 + anlotinib versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20200879Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab, anlotinib, sorafenib in hepatocellular carcinoma (HCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2020; status: completed.
02
Drugs
cadonilimabanlotinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200879.